Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Moodys
Federal Trade Commission
AstraZeneca
Baxter
Covington
Accenture
QuintilesIMS

Generated: October 17, 2018

DrugPatentWatch Database Preview

Darifenacin hydrobromide - Generic Drug Details

« Back to Dashboard

What are the generic sources for darifenacin hydrobromide and what is the scope of darifenacin hydrobromide patent protection?

Darifenacin hydrobromide is the generic ingredient in three branded drugs marketed by Macleods Pharms Ltd, Alembic Pharms Ltd, Anchen Pharms, Aurobindo Pharma Ltd, Cipla Ltd, Jubilant Generics, Torrent Pharms Ltd, and Apil, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are nineteen drug master file entries for darifenacin hydrobromide. Twelve suppliers are listed for this compound.

Pharmacology for darifenacin hydrobromide
Synonyms for darifenacin hydrobromide
(3S)-1-[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-|A-|A-diphenyl-3-pyrrolidineacetamide Hydrobromide
(S)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide hydrobromide
(S)-2-{1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl}-2,2-diphenylacetamide hydrobromide
[1-[2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL]-3-PYRROLIDNYL]-2,2-DIPHENYLACETAMIDE HYDROBROMIDE
133099-07-7
2-[(3S)-1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]-3-PYRROLIDINYL]-2,2-DIPHENYLACETAMIDE HYDROBROMIDE
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide hydrobromide
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide
2-[(3S)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenyl-acetamide hydrobromide
2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide hydrobromide
3-Pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, monohydrobromide, (3S)-
3-Pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, monohydrobromide, (S)-
3-PYRROLIDINEACETAMIDE, 1-[2-(2,3-DIHYDRO-5-BENZOFURANYL)ETHYL]-ALPHA,ALPHA-DIPHENYL-, HYDROBROMIDE (1:1), (3S)-
AB0073012
AC-1894
AC1L9FKV
AK326131
AKOS015969311
AN-6905
API0008085
BC003938
BC201082
CAS-133099-07-7
CCG-220969
CHEBI:31455
CHEMBL1200935
CR02EYQ8GV
CS-0380
D01699
Darifenacin (hydrobromide)
darifenacin HBr
Darifenacin hydrobromide (JAN/USAN)
Darifenacin hydrobromide [USAN]
Darifenacin hydrobromide, >=98% (HPLC)
Darifenacin hydrobromide, United States Pharmacopeia (USP) Reference Standard
Darilong
DSSTox_CID_26780
DSSTox_GSID_46780
DSSTox_RID_81899
DTXSID9046780
Enablex (TN)
ENABLEX HYDROBROMIDE
HY-A0012
KS-00000KBH
LS-186532
MCULE-9754914075
MFCD08141803
MolPort-003-846-139
NCGC00168775-01
NCGC00263922-02
PubChem14816
Q-101006
s3144
Tox21_112636
Tox21_112636_1
UK 88525-04 hydrobromide
UK-88525-04
UK-88525-04 (HYDROBROMIDE)
UNII-CR02EYQ8GV
UQAVIASOPREUIT-VQIWEWKSSA-N
W-5366
Z1691545283

US Patents and Regulatory Information for darifenacin hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Torrent Pharms Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 205209-001 Nov 17, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Alembic Pharms Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 207681-001 Dec 8, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Macleods Pharms Ltd DARIFENACIN darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 207302-002 Jul 28, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for darifenacin hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil ENABLEX darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 021513-001 Dec 22, 2004 ➤ Sign Up ➤ Sign Up
Apil ENABLEX darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 021513-002 Dec 22, 2004 ➤ Sign Up ➤ Sign Up
Apil ENABLEX darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 021513-002 Dec 22, 2004 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Moodys
Federal Trade Commission
AstraZeneca
Baxter
Covington
Accenture
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.